Related Experiment Videos
Two novel gene mutations in type I antithrombin deficiency.
K Niiya1, T Kiguchi, H Dansako
1Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School, Japan. kniiya@md.okayama-u.ac.jp
International Journal of Hematology
|January 17, 2002
Summary
Researchers identified two novel mutations in antithrombin (AT) deficiency, a genetic cause of recurrent venous thrombosis. These findings simplify the detection of AT mutations, improving diagnosis for thrombophilia patients.
Area of Science:
- Genetics
- Molecular Biology
- Hematology
Background:
- Type I antithrombin (AT) deficiency is a genetic disorder associated with recurrent venous thrombosis.
- Affected individuals often present with approximately 50% of normal AT protein levels.
- Standard diagnostic methods include functional and antigen assays for AT protein levels.
Observation:
- Southern blotting revealed no DNA abnormalities in affected individuals from two Japanese families.
- Direct sequencing of PCR products identified a novel heterozygous nonsense mutation (Glu306 stop) in exon 4 in one family.
- A novel heterozygous 9-bp deletion (His120, Phe121, Phe122 deletion) in exon 3a was identified in the second family.
Findings:
- Two distinct, novel heterozygous mutations in the antithrombin gene were identified in Japanese families with type I AT deficiency.
- The nonsense mutation in exon 4 and the 9-bp deletion in exon 3a were confirmed through subcloning and sequencing.
- Polymerase chain reaction (PCR) and subsequent sequencing of PCR product subclones proved effective for mutation detection and characterization.
Implications:
- These novel mutations expand the known genetic spectrum of antithrombin deficiency.
- The simplified PCR-based sequencing method facilitates accurate diagnosis and characterization of AT mutations.
- Improved understanding of AT mutations aids in managing patients with inherited thrombophilia and recurrent venous thrombosis.